182 related articles for article (PubMed ID: 35357770)
1. Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany.
Tergast TL; Blach S; Tacke F; Berg T; Cornberg M; Kautz A; Manns M; Razavi H; Sarrazin C; Serfert Y; van Thiel I; Zeuzem S; Wedemeyer H
J Viral Hepat; 2022 Jul; 29(7):536-542. PubMed ID: 35357770
[TBL] [Abstract][Full Text] [Related]
2. Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
Schorr O; Blach S; Thurnheer C; Ruis C; Dufour JF
PLoS One; 2022; 17(8):e0272518. PubMed ID: 35960770
[TBL] [Abstract][Full Text] [Related]
3. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
[TBL] [Abstract][Full Text] [Related]
4. Securing wider EU commitment to the elimination of hepatitis C virus.
Wedemeyer H; Tergast TL; Lazarus JV; Razavi H; Bakoyannis K; Baptista-Leite R; Bartoli M; Bruggmann P; Buşoi CS; Buti M; Carballo M; Castera L; Colombo M; Coutinho RS; Dadon Y; Esmat G; Esteban R; Farran JC; Gillyon-Powell M; Goldberg D; Hutchinson S; Janssen HLA; Kalamitsis G; Kondili LA; Lambert JS; Marinho RT; Maticic M; Patricello A; Peck-Radosavljevic M; Pol S; Poljak M; Pop C; Sokol T; Sypsa V; Tözün N; Younossi Z; Aghemo A; Papatheodoridis GV; Hatzakis A
Liver Int; 2023 Feb; 43(2):276-291. PubMed ID: 36196744
[TBL] [Abstract][Full Text] [Related]
5. Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis.
Marquez LK; Ingiliz P; Boesecke C; Krznaric I; Schewe K; Lutz T; Mauss S; Christensen S; Rockstroh JK; Jain S; He F; Wertheim JO; Martin NK
PLoS One; 2022; 17(5):e0267853. PubMed ID: 35551326
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19.
Blach S; Blomé M; Duberg AS; Jerkeman A; Kåberg M; Klasa PE; Lagging M; Razavi-Shearer D; Razavi H; Aleman S
Liver Int; 2021 Sep; 41(9):2024-2031. PubMed ID: 34051065
[TBL] [Abstract][Full Text] [Related]
7. Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress.
Blach S; Brown KA; Brown RS; Gholam PM; Terrault NA; Estes C; Razavi HA
J Infect Public Health; 2023 Jan; 16(1):64-70. PubMed ID: 36473359
[TBL] [Abstract][Full Text] [Related]
8. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
[TBL] [Abstract][Full Text] [Related]
9. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT
PLoS One; 2021; 16(9):e0257369. PubMed ID: 34529711
[TBL] [Abstract][Full Text] [Related]
10. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
11. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
12. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.
Polaris Observatory HCV Collaborators
Lancet Gastroenterol Hepatol; 2022 May; 7(5):396-415. PubMed ID: 35180382
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
14. Forecasting the long-term impact of COVID-19 on hepatitis C elimination plans in Italy: A mathematical modelling approach.
Kondili LA; Andreoni M; Aghemo A; Mastroianni CM; Merolla R; Gallinaro V; D'Offizi G; Craxì A
Liver Int; 2023 Dec; 43(12):2615-2624. PubMed ID: 37735959
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
European Union HCV Collaborators
Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
[TBL] [Abstract][Full Text] [Related]
16. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
Tada T; Toyoda H; Kumada T; Kurisu A; Sugiyama A; Akita T; Ohisa M; Aikata H; Miki D; Chayama K; Tanaka J
J Viral Hepat; 2021 Mar; 28(3):538-547. PubMed ID: 33215790
[TBL] [Abstract][Full Text] [Related]
17. The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia.
Gamkrelidze A; Handanagic S; Shadaker S; Turdziladze A; Tsereteli M; Getia V; Aslanikashvili A; Surguladze S; Gvinjilia L; Kuchuloria T; Tskhomelidze I; Armstrong PA
Public Health; 2022 Apr; 205():182-186. PubMed ID: 35305459
[TBL] [Abstract][Full Text] [Related]
18. A micro-elimination approach to addressing hepatitis C in Turkey.
Idilman R; Razavi H; Robbins-Scott S; Akarca US; Örmeci N; Kaymakoglu S; Aygen B; Tozun N; Güner R; Bodur H; Lazarus JV
BMC Health Serv Res; 2020 Mar; 20(1):249. PubMed ID: 32209103
[TBL] [Abstract][Full Text] [Related]
19. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
Fraňková S; Urbánek P; Husa P; Němeček V; Razavi H; Razavi-Shearer D; Chlíbek R; Šperl J
Cent Eur J Public Health; 2019 Jun; 27(2):93-98. PubMed ID: 31241282
[TBL] [Abstract][Full Text] [Related]
20. Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis.
Shakeri A; Konstantelos N; Chu C; Antoniou T; Feld J; Suda KJ; Tadrous M
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
